HC Wainwright

Plug Power Misses Q2 Revenues, Analysts Focus On Electrolyzer Deployments: 'The Bar Was Set Low'

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'

Coinbase Global Is 'Doing Almost Everything Right': 7 Analysts React To Q1 Results

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'

Coinbase Global Is 'Doing Almost Everything Right': 7 Analysts React To Q1 Results

Coinbase Q1 Earnings Preview: What Analysts Are Saying, SEC Regulation & Other Items To Watch

'Crypto Winter Is Over': Coinbase Analyst Foresees Market Share Domination In 2023

Coinbase Q1 Earnings Preview: What Analysts Are Saying, SEC Regulation & Other Items To Watch

'Crypto Winter Is Over': Coinbase Analyst Foresees Market Share Domination In 2023

Why This PepGen Analyst Is Bullish On The Biotech Stock

These 2 Analysts Are Bullish Despite EV Equipment Maker Blink Charging's Wider Loss

HC Wainwright Recent News

Why InflaRx Shares Are Ripping Higher Thursday

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.

Why Plug Power Analysts Are Bullish After Hydrogen Green Energy Company's Investor Day

Plug Power Inc. (NASDAQ: PLUG) announced an acquisition, partnerships, products and updated guidance at its 2021 Plug Symposium.

Psyched: Field Trip Gets $20 Price Target, DEA Seeks To Increase Psilocybin Production Limits, Synthesis Closes $7.25M Series A

Field Trip Stock Could Climb 300% In One Year

On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ: FTRP), a company in the psychedelics space, which is developi

What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.

Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated

Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp.

Wall Street Analysts See These 4 Stocks As Winners Moving Into December

The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ:

Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval

G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results

Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?

Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade

Sell-Side Analysts See Upside Potential In Zynerba

HC Wainwright: Celyad's CAR-T Pipeline Has Potential

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity

Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades

HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside

Analysts See 100% Upside To Rigel After Tavalisse Approval

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Analyst Remains Confident In Corium Despite Bad FDA News